Advances in Cancer Research
Academic Press
Published on 18. September 1992
340 pages
978-0-08-056241-4 (ISBN)
Description
Advances in Cancer Research
More details
Other editions
Additional editions
George F. Vande Woude | George F. Vande Woude | G. Klein
Advances in Cancer Research: v. 59
Book
08/1992
Academic Press
€75.64
Article exhausted; check different version
Persons
Content
- Front Cover
- Advances in Cancer Research, Volume 59
- Copyright Page
- Contents
- Contributor to Volume, 59
- Preface
- Chapter 1. Lev Zilber, The Personality and the Scientist
- I. Introduction
- II. First Steps in Science: The First Discovery
- III. The First Victory and the First Arrest
- IV. From Bacteria to Viruses
- V. An Exploit in the Taiga
- VI. Science behind Bars and Barbed Wire
- VII. Finding the Family
- VIII. After the War: Virology and Immunology of Cancer
- IX. The Last Outburst of Stalin's Tyranny
- X. Reunification with the World Scientific Community
- XI. Discovery of Pathogenicity of Rous Sarcoma Virus for Mammals
- XII. In Search of Oncogenic Viruses
- XIII. The Virogenic Concept of the Origin of Tumors
- XIV. Development of Tumor Immunology
- XV. The Last Efforts and the Last Days
- XVI. Legacy
- References
- Chapter 2. The Genetics of Wilms' Tumor
- I . Introduction
- II. Histology and Clinical Considerations
- III. The Knudson Model
- IV. Genetic Loci Associated with Wilms' Tumor
- V. Isolation of the WTI Gene at 11p13
- VI. WTI: Characterization of a Novel Tumor Suppressor Gene
- VII. Functional Studies and Animal Models
- VIII. Conclusions
- References
- Chapter 3. p53 Expression in Human Breast Cancer
- I. Introduction
- II. Discovery of p53
- III. Dominant Transforming Oncogene
- IV. Recessive Oncogene
- V. Dominant Negative Function and Gain in Function Mutants
- VI. Normal Function and Regulation of p53
- VII. Mutations in p53 and Interactions with Viral Proteins
- VIII. Loss of Heterozygosity and p53 Mutations
- IX. Different Functionai Mutations and Mutational Profiles
- X. Methods to Assay p53 in Human Cancer
- XI. Studies in Breast Cancer
- XII. Loss of Heterozygosity
- XIII. Immunochemistry
- XIV. Mutations
- XV. Familial Breast Cancer and Li Fraumeni Synodrome
- XVI. Expression of p53 with Other Oncogenes and Receptors
- XVII. Prognosis
- XIX. Therapeutic Possibilities
- References
- Chapter 4. c-erbA: Protooncogene or Growth Suppressor Gene?
- I . Introduction
- II. Avian Erythroblastosis Virus as a Model for Cooperativity of Oncogenes
- III. The Protooncogene c-erbA Encodes a Thyroid Hormone Receptor
- IV. Multiple c-erbA Loci
- V. Structural Differences between v-erbA and c-erbA
- VI. Functional Properties of the ErbA Proteins
- VII. Mutations Affecting the Biological Activity of v-erbA
- VIII. c-ErbA Regulation of Erythroid Differentiation and Gene Expression
- IX. c-erbA: Protooncogene or Growth Suppressor Gene?
- X. Mutations Affecting c-erbA Function
- XI. Current Concepts and Open Questions
- References
- Chapter 5. The FGF Family of Growth Factors and Oncogenes
- I. Introduction
- II. Protein Structure
- III. The FGF Genes and Their Expression
- IV. FGF Receptors
- V. Interaction with Extracellular Matrix
- VI. Biological Function
- VII. Oncogenic Potential
- VIII. Involvement of FGFs in Tumors
- IX. Concluding Remarks
- References
- Chapter 6. Hepatitis B Viruses and Hepatocellular Carcinoma
- I. Introduction
- II. Epidemiology: Clinical and Immunological Aspects
- III. Pathogenicity of Hepadnaviruses: Striking Similarities and Obvious Differences
- IV. Hepadnavirus Genomes
- V. Potential Oncogenic Properties of Viral Proteins
- VI. Integrated State of Viral DNA in Chronic Infections and Hepatocellular Carcinoma
- VII. Genetic Alterations in HBV-Related Hepatocellular Carcinoma
- VIII. Conclusions
- References
- Chapter 7. Cytotoxic Lymphocytes:Specificity,Surveillance and Escape
- I. Introduction
- II. The molecular basis of Peptide MHC Association
- III. HLA-A2 Interaction with Influenza Matrix Peptide(58-66)
- IV. Antigen Processing
- V. CTL Function and Escape from CTL Recognition
- VI. Conclusion
- References
- Chapter 8. Cancer Immunotheraphy: Are the Results Discouraging? Can They Be Improved?
- I. Introduction
- II. Critical Factors in Cancer Immunotherapy
- III. Current Immunotheraphy Strategies
- IV. Attempt to Improve Cancer Immunotheraphy
- V. Conclusions
- References
- Index
